hypertrophic

Trapencaine is a newly synthesized carbamate type local anesthetic that induces conformational changes in sodium channels on hypertrophic cell membranes.

Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Methyl Aminolevulinate Hydrochloride (5-Aminolevulinic acid methyl ester) is commonly used in photosentizer reagents for photodynamic therapy to treat conditions such as Acne vulgaris and hypertrophic scarring.

Fropofol (2-fluoro-1,3-diisopropylbenzene) is a non-anesthetic small molecule that specifically reduces myocardial contractility and inhibits myofilament contraction. It can be used in research on hypertrophic cardiomyopathy and cardiovascular diseases.

GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression.GATA4-NKX2-5-IN-1  dose-dependently inhibits the GATA4–NKX2-5 tran

ST2-IN-1 (compound 31) is an inhibitor of Stimulation-2 (ST2) with an IC50 of 7 μM in AlphaLISA assays and 7.19 μM in HEK-Blue assays. This compound effectively attenuates the ST2 IL-33 signaling pathway in human hypertrophic cells.

JNJ-28330835 is a selective androgen receptor modulator with minimal prostate hypertrophic activity.

Ethyl L-leucinate HCl has been used as a hypertrophic agent to monitor its effects on myotubes and has also been used as a component of PMG media for culturing yeast.

Cibenzoline is an antiarrhythmic agent that inhibits the KATP channel by directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline shows little anticholinergic activity. Cibenzoline markedly reduces LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for hypertrophic obstructive cardiomyopathy research[1][2].

CCG-273463 is a potent, covalent, selective inhibitor of GRK5 (IC50: 9 nM). CCG-273463 can be used to study heart failure, hypertrophic cardiomyopathy and cancer.

JB062 is a chemical compound acting as a nonmuscle myosin inhibitor, exhibiting IC50 values of 1.6, 5.4, and >100 μM against skeletal muscle myosin, cardiac muscle myosin, and smooth muscle myosin II, respectively. It selectively exhibits cytotoxicity towards human cancer cells without affecting normal cells. The compound is applicable in research fields concerning muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

JB002, a myosin II inhibitor, exhibits potent activity with an IC50 of ≤10 μM. It holds potential for research applications in muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.